Canopy Growth Corporation

CGC Healthcare Drug Manufacturers Specialty & Generic

Canopy Growth Corporation’s revenue for fiscal 2026 (year ended March 2026) was $206.0 million, up 6.55% from fiscal 2025. In the quarter to June 2026, revenue grew 12.4%, EPS grew 87.5%, free cash flow fell 117.6% and total debt fell 18.7%, each against the same quarter a year earlier. Dividend growth for three consecutive years, operating cash flow growth for three.

0.71 0.03 −4.05%
Market cap
$311.2M
P/E
0.0×
Fwd P/E
−5.6×
Dividend yield
—
F-score
5/9
Altman Z
−13.21
Beneish M
−3.49
Dividend safety
n/a

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22 Mar '23 Mar '24 Mar '25 Mar '26
Net Income
(12.69) (42.24) (510.61) (1,043.08) (1,266.31) (255.68) (2,503.67) (358.55) (434.19) (190.29)
Operating Cash Flow
(20.64) (63.59) (396.63) (580.87) (352.98) (435.45) (421.78) (209.01) (119.12) (46.18)
Investing cash flow
(14.17) (174.44) (2,459.72) (261.37) (670.06) 184.15 327.85 179.09 (34.35) (15.45)
Financing cash flow
100.63 410.27 4,447.95 (42.97) 958.57 (36.33) (14.90) (344.75) 106.84 240.60
Ending Cash
77.55 251.66 1,890.39 979.73 875.11 619.10 512.16 126.24 81.80 263.96
Other line items

Show all line items

In millions of $ except per-share values · columns are period end dates